Your Global Leader in Stem Cell Market Research
On December 3, 2019, Adaptimmune Therapeutics (Nasdaq:ADAP) announced it has been granted an Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. FDA for ADP-A2M4 in the treatment of Synovial Sarcoma. Previously, the FDA had awarded an Orphan Drug Designation (ODD) to ADP-A2M4 for the treatment of soft tissue sarcomas.
This RMAT designation represents the 38th publicly announced RMAT within the United States. [Read more…]
As of today, the list of publicly announced RMAT’s has risen to 38. However, the U.S. FDA states it has received 115 total requests for RMAT designations and granted 44.
This means that slightly over one-third of RMAT applications get approved.
Adaptimmune Therapeutics T-cell therapy ADP-A2M4 for the treatment of Synovial Sarcoma was the most recent addition on December 3, 2019.
TORRANCE, Calif. – Kataoka-SS America, a US subsidiary of Kataoka Corporation Kyoto Japan, has launched its sales of their Cell Processor CPD-017 to the U.S. market. Kataoka`s Cell Processor uses laser technology to scan, identify, and irradiate spontaneously differentiated cells without dissociation or applied stress to the cells.
With the CPD-017, the process time of purifying induced pluripotent stem cell (iPSC) is significantly reduced and the adherent cell colonies can maintain a stress-free healthy condition. [Read more…]
Cord Blood Registry (CBR), a California Cryobank Life Sciences company, has announced it will acquire Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services. [Read more…]
REDWOOD CITY, Calif., Oct. 22, 2019 — Synthego, the leading genome engineering company, announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. [Read more…]
